Yep. That was an interesting point. I also liked:

Yep. That was an interesting point. I also liked:

"We look forward to coming together with a strategic partner that can help CytoDyn get this molecule over the finish line."

Which I'm all for. Let's partner with a major player and quit fucking around. Of course nothing is ever 100% clear because he also says this:

"...and will hopefully lift the hold. Once that is taken care of, we plan to go out and raise financing to fund operations. Once the financing has been stabilized, we will bring people onboard with relevant biotech experience and expertise that can support our development goals, which include starting a NASH trial and continuing to invest in and advance our long-acting CCR5 molecule. A corporate rebranding campaign will also be implemented to put some of these issues in the past while creating a new face for the company."

So are we raising funds to move forward or are we partnering to move forward?

After the last call I felt pretty strongly that Cyrus intends to raise funds to start the Nash trial and that his partnership references were for advancing oncology. But in this interview he seems to say it both ways. We're going to raise funds for operations and we're looking to come together with a strategic partner to get LL over the finish line.

I mean, signing a deal with a partner that brings in funding is technically raising financing. I guess it could be both of these things at the same time.

I also wonder about when this was actually recorded. Because didn't Cyrus say on the last call that we only had one more section to submit to the FDA while this article mentions that of the five things requested by the FDA there were still two outstanding that he anticipated getting submitted very soon?